Literature DB >> 26595071

Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study.

M Wu1, J Sun1, Y Zhang1, F Huang1, H Zhou1, Z Fan1, L Xuan1, G Yu1, X Guo1, M Dai1, R Feng1, Q Liu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26595071     DOI： 10.1038/bmt.2015.281

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

Review 1.  Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.

Authors:  Deepa Jagadeesh; Bruce A Woda; Jacqueline Draper; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2012-03

Review 2.  Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.

Authors:  Anne H Blaes; Bruce A Peterson; Nancy Bartlett; David L Dunn; Vicki A Morrison
Journal:  Cancer       Date:  2005-10-15       Impact factor: 6.860

3.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.

Authors:  R E Curtis; L B Travis; P A Rowlings; G Socié; D W Kingma; P M Banks; E S Jaffe; G E Sale; M M Horowitz; R P Witherspoon; D A Shriner; D J Weisdorf; H J Kolb; K M Sullivan; K A Sobocinski; R P Gale; R N Hoover; J F Fraumeni; H J Deeg
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

4.  Posttransplant lymphoproliferative disorder: significance of central nervous system involvement.

Authors:  J F Buell; T G Gross; M J Hanaway; J Trofe; P Roy-Chaudhury; M R First; E S Woodle
Journal:  Transplant Proc       Date:  2005-03       Impact factor: 1.066

5.  Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.

Authors:  James L Rubenstein; Jane Fridlyand; Lauren Abrey; Arthur Shen; Jon Karch; Endi Wang; Samar Issa; Lloyd Damon; Michael Prados; Michael McDermott; Joan O'Brien; Chris Haqq; Marc Shuman
Journal:  J Clin Oncol       Date:  2007-02-20       Impact factor: 44.544

6.  EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.

Authors:  C P Fox; D Burns; A N Parker; K S Peggs; C M Harvey; S Natarajan; D I Marks; B Jackson; G Chakupurakal; M Dennis; Z Lim; G Cook; B Carpenter; A R Pettitt; S Mathew; L Connelly-Smith; J A L Yin; M Viskaduraki; R Chakraverty; K Orchard; B E Shaw; J L Byrne; C Brookes; C F Craddock; S Chaganti
Journal:  Bone Marrow Transplant       Date:  2013-11-11       Impact factor: 5.483

7.  Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

Authors:  Andrew M Evens; Kevin A David; Irene Helenowski; Beverly Nelson; Dixon Kaufman; Sheetal M Kircher; Alla Gimelfarb; Elise Hattersley; Lauren A Mauro; Borko Jovanovic; Amy Chadburn; Patrick Stiff; Jane N Winter; Jayesh Mehta; Koen Van Besien; Stephanie Gregory; Leo I Gordon; Jamile M Shammo; Scott E Smith; Sonali M Smith
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

8.  Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.

Authors:  Robert Cavaliere; Gina Petroni; Maria B Lopes; David Schiff
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

9.  Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.

Authors:  Ola Landgren; Ethel S Gilbert; J Douglas Rizzo; Gérard Socié; Peter M Banks; Kathleen A Sobocinski; Mary M Horowitz; Elaine S Jaffe; Douglas W Kingma; Lois B Travis; Mary E Flowers; Paul J Martin; H Joachim Deeg; Rochelle E Curtis
Journal:  Blood       Date:  2009-03-05       Impact factor: 22.113

10.  Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Li Xuan; Xinmiao Jiang; Jing Sun; Yu Zhang; Fen Huang; Zhiping Fan; Xutao Guo; Min Dai; Can Liu; Guopan Yu; Xian Zhang; Meiqing Wu; Xiaojun Huang; Qifa Liu
Journal:  Transplantation       Date:  2013-09       Impact factor: 4.939
View more
  6 in total

Review 1.  Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder.

Authors:  Ajay Major; Manali Kamdar
Journal:  Curr Treat Options Oncol       Date:  2018-05-24

Review 2.  Biology of CNS lymphoma and the potential of novel agents.

Authors:  James L Rubenstein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  Central nervous system post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.

Authors:  Hikaru Sakamoto; Hidehiro Itonaga; Jun Taguchi; Takeharu Kato; Yasushi Sawayama; Tomayoshi Hayashi; Shiro Baba; Masako Moriuchi; Koichi Ohshima; Shinichiro Yoshida; Yukiyoshi Moriuchi; Yasushi Miyazaki
Journal:  Leuk Res Rep       Date:  2019-04-22

4.  [How I diagnose and treat post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation].

Authors:  L P Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-11-14

5.  Epstein-Barr Virus Encephalitis and Disseminated Adenovirus Infection after Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation for a Patient with Ph-Like Acute Lymphoblastic Leukemia.

Authors:  Xiao Zhou; Xianmin Song; Liping Wan
Journal:  Case Rep Oncol       Date:  2022-03-14

6.  A Case of Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Haploidentical Stem Cell Transplantation in a Patient With Acute Lymphoblastic Leukemia.

Authors:  Haibo Zhu; Qing Li; Yunyang Liu; Xuequan Feng; Qi Deng
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.139
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.